Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

There are currently no events to display.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

07/13/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Cytokinetics, Inc. (NASDAQ:CYTK) today announced The Lancet published results from a Phase 2 clinical trial evaluating omecamtiv mecarbil in patients with chronic heart failure.
Toggle Summary Phase I Clinical Trial Data Relating to Omecamtiv Mecarbil Presented at the 2010 Heart Failure Society of America Annual Meeting
Investigators Conclude That Omecamtiv Mecarbil Improved Left Atrial Performance in Healthy Volunteers SOUTH SAN FRANCISCO, CA, Sep 14, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional Phase I clinical trial data relating to omecamtiv mecarbil
Toggle Summary Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures of Vital Capacity in Patients With ALS
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced results from the first part of a research collaboration to refine and prospectively validate an Origent computer model to predict the course of
Toggle Summary Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALS
Origent Receives ALS Association Grant to Enable Research Partnership SOUTH SAN FRANCISCO, Calif., March 31, 2016 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced a research collaboration to refine and prospectively validate an Origent

EVENTS

There are currently no events to display.